← All trials
NCT05394012
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 31, 2022
- Primary completion
- Feb 28, 2023
- Completion date
- Jun 30, 2023
- First posted
- May 27, 2022
- Last posted
- Nov 18, 2022
- Enrollment
- 120
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Walvax Biotechnology Co., Ltd.Lead sponsor
- Walvax Biotechnology Co., Ltd.Study director
- Shanghai RNACure Biopharma Co., Ltd.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.